Abstract
Background: Antiplatelet agents are widely used for cardiovascular diseases, but their pleiotropic effects in sepsis are controversial. Objective: To investigate the association between antiplatelet agents and the survival benefit for sepsis patients. Design: A nationwide population-based cohort and nested case–control study. Setting: Taiwan National Health Insurance database. Participants: All patients (age ≥18 years) who were hospitalized for sepsis between January 2000 and December 2010. Measurements: Conditional logistic regression was used to adjust for confounding. Adjusted odd ratios (ORs) were used to compare the mortality rate due to sepsis in antiplatelet drug users and nonusers. Results: Of 683,421 included patients, 229,792 (33.6 %) patients died during hospitalization for sepsis, and the rest (64.4 %) survived to discharge. Use of antiplatelet agents before admission was associated with a lower risk of mortality in sepsis patients (aOR 0.82, 95 % confidence interval [CI] 0.81–0.83, P < 0.001). By using another case–control study design, the beneficial effect was more significant in current users (aOR 0.78, 95 % CI 0.76–0.79) than in recent users (aOR 0.88, 95 % CI 0.85–0.91), but was not significant in past users (aOR 1.00, 95 % CI 0.98–1.02). Limitations: Observational study. Conclusions: Prior use of antiplatelet agents was associated with a survival benefit in sepsis patients.
| Original language | English |
|---|---|
| Pages (from-to) | 806-813 |
| Number of pages | 8 |
| Journal | Intensive Care Medicine |
| Volume | 41 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - May 1 2015 |
Fingerprint
Keywords
- Antiplatelet
- Mortality
- Sepsis
ASJC Scopus subject areas
- Critical Care and Intensive Care Medicine
Cite this
Association of prior antiplatelet agents with mortality in sepsis patients : a nationwide population-based cohort study. / Tsai, Min Juei; Ou, Shuo Ming; Shih, Chia Jen; Chao, Pei wen; Wang, Lan Fu; Shih, Yu Ning; Li, Szu Yuan; Kuo, Shu Chen; Hsu, Yen Tao; Chen, Yung Tai.
In: Intensive Care Medicine, Vol. 41, No. 5, 01.05.2015, p. 806-813.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Association of prior antiplatelet agents with mortality in sepsis patients
T2 - a nationwide population-based cohort study
AU - Tsai, Min Juei
AU - Ou, Shuo Ming
AU - Shih, Chia Jen
AU - Chao, Pei wen
AU - Wang, Lan Fu
AU - Shih, Yu Ning
AU - Li, Szu Yuan
AU - Kuo, Shu Chen
AU - Hsu, Yen Tao
AU - Chen, Yung Tai
PY - 2015/5/1
Y1 - 2015/5/1
N2 - Background: Antiplatelet agents are widely used for cardiovascular diseases, but their pleiotropic effects in sepsis are controversial. Objective: To investigate the association between antiplatelet agents and the survival benefit for sepsis patients. Design: A nationwide population-based cohort and nested case–control study. Setting: Taiwan National Health Insurance database. Participants: All patients (age ≥18 years) who were hospitalized for sepsis between January 2000 and December 2010. Measurements: Conditional logistic regression was used to adjust for confounding. Adjusted odd ratios (ORs) were used to compare the mortality rate due to sepsis in antiplatelet drug users and nonusers. Results: Of 683,421 included patients, 229,792 (33.6 %) patients died during hospitalization for sepsis, and the rest (64.4 %) survived to discharge. Use of antiplatelet agents before admission was associated with a lower risk of mortality in sepsis patients (aOR 0.82, 95 % confidence interval [CI] 0.81–0.83, P < 0.001). By using another case–control study design, the beneficial effect was more significant in current users (aOR 0.78, 95 % CI 0.76–0.79) than in recent users (aOR 0.88, 95 % CI 0.85–0.91), but was not significant in past users (aOR 1.00, 95 % CI 0.98–1.02). Limitations: Observational study. Conclusions: Prior use of antiplatelet agents was associated with a survival benefit in sepsis patients.
AB - Background: Antiplatelet agents are widely used for cardiovascular diseases, but their pleiotropic effects in sepsis are controversial. Objective: To investigate the association between antiplatelet agents and the survival benefit for sepsis patients. Design: A nationwide population-based cohort and nested case–control study. Setting: Taiwan National Health Insurance database. Participants: All patients (age ≥18 years) who were hospitalized for sepsis between January 2000 and December 2010. Measurements: Conditional logistic regression was used to adjust for confounding. Adjusted odd ratios (ORs) were used to compare the mortality rate due to sepsis in antiplatelet drug users and nonusers. Results: Of 683,421 included patients, 229,792 (33.6 %) patients died during hospitalization for sepsis, and the rest (64.4 %) survived to discharge. Use of antiplatelet agents before admission was associated with a lower risk of mortality in sepsis patients (aOR 0.82, 95 % confidence interval [CI] 0.81–0.83, P < 0.001). By using another case–control study design, the beneficial effect was more significant in current users (aOR 0.78, 95 % CI 0.76–0.79) than in recent users (aOR 0.88, 95 % CI 0.85–0.91), but was not significant in past users (aOR 1.00, 95 % CI 0.98–1.02). Limitations: Observational study. Conclusions: Prior use of antiplatelet agents was associated with a survival benefit in sepsis patients.
KW - Antiplatelet
KW - Mortality
KW - Sepsis
UR - http://www.scopus.com/inward/record.url?scp=84937761924&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84937761924&partnerID=8YFLogxK
U2 - 10.1007/s00134-015-3760-y
DO - 10.1007/s00134-015-3760-y
M3 - Article
C2 - 25829229
AN - SCOPUS:84937761924
VL - 41
SP - 806
EP - 813
JO - Intensive Care Medicine
JF - Intensive Care Medicine
SN - 0342-4642
IS - 5
ER -